ストックスクリーナーアプリを入手
2.66
5.93%
0.13
前日終値:
$2.53
開ける：
$2.55
24時間の取引高:
38,176
Relative Volume:
0.06
時価総額：
$22.45M
収益：
$2.38M
当期純損益:
$-12.40M
株価収益率:
-0.4116
EPS:
-6.4626
ネットキャッシュフロー:
$-18.68M
1週間 パフォーマンス:
+4.69%
1か月 パフォーマンス:
-9.46%
6か月 パフォーマンス:
-75.96%
1年 パフォーマンス:
-62.92%
1日の値動き範囲:
$2.55
$2.69
1週間の範囲:
$2.45
$2.7356
52週間の値動き範囲:
$2.0223
$22.20
Femasys Inc Stock (FEMY) Company Profile
Compare FEMY vs ISRG, BDX, RMD, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
2.68 | 23.28M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
399.64 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
181.54 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
224.67 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
65.46 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.98 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-20 | 開始されました | Laidlaw | Buy |
Femasys Inc (FEMY) 最新ニュース
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance
Femasys Company Profile & Introduction - Moomoo
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
FEMASYS INC (FEMY) Stock Price & Overview - ChartMill
Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus
FemasysFiles For Resale Of Up To 28,124,997 Shares Of Common StockSEC Filing - TradingView
Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan
Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Femasys Inc (FEMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan
Femasys (FEMY) Stock News & Analysis - TechStock²
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayValue Stock Ideas - vinanet.vn
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingVolume Dry Up - vinanet.vn
Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm
Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com
Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance
FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan
Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record
Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView
Femasys secures $30 million to advance fertility portfolio - The Pharma Letter
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan
FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo
Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan
Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Femasys (FEMY) gains Rosalind-linked holder with potential 9.99% equity stake - Stock Titan
FEMY Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Slips 2.55%Earnings Decline Risk - vinanet.vn
FEMY Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share, Yet Shares Dip 2.34%ROIC Trend Report - Vinanet
Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents - marketscreener.com
Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share Beats Estimates by 34.64% - dars.gov.et
Femasys receives patents for FemBloc birth control polymer By Investing.com - Investing.com South Africa
Femasys receives patents for FemBloc birth control polymer - Investing.com
Femasys Secures New U.S. and International Patents for FemBloc Blended Polymer, Expanding Global IP Protection - Quiver Quantitative
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents - Yahoo Finance
Femasys COO John Canning buys $14,000 in FEMY stock - Investing.com India
Femasys Inc (FEMY) 財務データ
収益
当期純利益
現金流量
EPS
Femasys Inc (FEMY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sipos Jeremy Alexander | Chief Technology Officer |
Aug 07 '26 |
Buy |
3.20 |
3,125 |
10,000 |
3,125 |
| Canning John Charles | Chief Operating Officer |
Aug 07 '26 |
Buy |
3.20 |
4,375 |
14,000 |
4,375 |
| Elefant Dov | Chief Financial Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
| Lee-Sepsick Kathy | Chief Executive Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
2.08%
大文字化:
|
ボリューム (24 時間):